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Background: Patients with luminal HER2-negative tumours have a favourable prognosis. However, there is a
subpopulation in which poorer outcomes are obtained with endocrine therapy alone. This subpopulation is
considered to benefit from chemotherapy. However, the significance of chemotherapy for those with luminal
tumours has decreased due to recent changes in treatment strategies. Thus, it is often difficult to determine
whether we should recommend chemotherapy to such patients in clinical practice. We investigated Ki67 expression,
as a means of predicting the responses of luminal HER2-negative breast cancer patients to neo-adjuvant
chemotherapy (NAC), in order to identify a subpopulation that would benefit from these treatments.
Methods: We enrolled 114 luminal HER2-negative breast cancer patients undergoing surgery after NAC. Biomarkers
were examined using biopsy specimens obtained prior to treatment, to avoid any chemotherapy-related effects.
Chemotherapy effects were determined employing operative specimens and we defined pathological complete
response (pCR) as invasive nest disappearance, based only on the primary breast tumour. We applied receiver operating
characteristic curve analysis to data from our 114 patients, to investigate Ki67 expression as a predictor of pCR.
Results: The pCR rate was significantly higher for tumours with high Ki67 expression (p < 0.01) and all patients who
obtained pCR remained recurrence-free during the median 58-month observation period. We identified 35% as the
Ki67 cut-off value which distinguishes those with a pCR from other cases. Another dataset, comprised of 196 patients
with a median 29-month observation period, was recruited for validation. Disease-free survival was found to be
significantly (p < 0.01) lower in the patients with tumours in which Ki67 expression was higher than 35%.
Conclusion: Our results raise the possibility of the luminal HER2-negative subpopulation with Ki67 expression higher
than 35% benefiting from chemotherapy, as evidenced by improved survival.
Keywords: Ki67, Cut-off value, Luminal breast cancer, Neo-adjuvant chemotherapy, Pathological complete responseBackground
Luminal breast cancer, a molecular tumour classification
subtype, is characterised by being estrogen receptor (ER)
and/or progesterone receptor (PR) positive and respond-
ing well to endocrine therapy [1,2]. Because overexpres-
sion of human epidermal growth factor receptor (HER2)
worsens patient outcomes, among all subtypes, luminal
HER2-negative carries the most favourable prognosis.* Correspondence: yoshiyahorimoto@hotmail.com
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unless otherwise stated.The majority of patients with luminal HER2-negative
tumours would be advised to receive only adjuvant
endocrine therapy after surgery [2,3]. However, there is
a luminal HER2-negative subpopulation in which poorer
outcomes can be expected with hormone therapy alone;
these patients would benefit from chemotherapy. On the
other hand, the significance of chemotherapy for patients
with luminal tumours is now controversial in terms of
both efficacy and adverse effects [2,4,5]. Thus, we often
face difficulty in determining whether we should recom-
mend (neo-) adjuvant chemotherapy to such patients in
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http://www.biomedcentral.com/1471-2407/14/550Ki67, also known as MKI67, a nuclear protein associ-
ated with cellular proliferation, is a well-established
marker for predicting the outcomes of patients with lu-
minal breast cancer [6-10]. As a tumour with high Ki67
expression carries a poor prognosis, the expression level
of this marker can have a major impact on treatment
decisions particularly for patients with luminal HER2-
negative tumours. According to biological differences,
hormone receptor positive breast cancer is categorised
into two groups: luminal A-like and B-like tumours with
good and poor prognoses, respectively [1]. These two
groups can be approximately distinguished based on
low and high expressions of Ki67. Since the St. Gallen
consensus in 2011, the well-known value of “14%” has
been regarded as the Ki67 cut-off value for distinguish-
ing between luminal A-like and B-like tumours and, as
an index, it serves as the basis for making treatment
decisions [2,7,8,11]. Moreover, luminal tumours with
high Ki67 expression reportedly respond well to
chemotherapy [10,12,13], probably reflecting their high
proliferative activity.
The aim of chemotherapy is to improve patient out-
comes, as represented by overall survival. Thus, the only
means of definitively evaluating treatments is to collect
long-term postoperative outcome data but this would be
very time-consuming, probably taking at least 10 years.
To solve this problem, the effects of treatments are actu-
ally evaluated based on pathological findings in the NAC
setting. Indeed, the chemo-effect, i.e. whether or not a
patient has obtained pCR, has been validated as a surro-
gate marker of long-term survival [14,15], although the
significance of pCR might vary among luminal and other
breast cancer subtypes [4,5,16].
Herein, we investigated Ki67 expression to predict the
responses of luminal HER2-negative breast cancer patients




We enrolled 114 patients with luminal HER2-negative
invasive breast cancer, who underwent surgery after re-
ceiving NAC at our hospital during the 2006 through
2011 period. All tumours were ER positive and HER2
negative. We excluded HER2-positive cases from this
study since their tumours have different biological charac-
teristics, necessitating additional adjuvant treatments. As to
NAC regimens, 108 of the 114 patients were given 4 cycles
of CEF (C: cyclophosphamide 500 mg/m2, E: epirubicin 75
or 100 mg/m2, F: 5-FU 500 mg/m2), followed by taxanes
(12 weeks of paclitaxel: 80 mg/m2 or 4 cycles of docetaxel:
75 mg/m2), prior to surgery. Five other patients received
only CEF while one was given only a taxane, due to car-
diac dysfunction. As to adjuvant treatment, 110 of the114 patients (96%) had a history of adjuvant endocrine
treatment after surgery according to menstruation status.
We administered aromatase inhibitors to 75 patients, tam-
oxifen to 19 and tamoxifen with a luteinising hormone-
releasing hormone analogue to 16. This study was carried
out with approval from the ethics committee of Juntendo
University Hospital (reference no. 21–570) and written in-
formed consent was obtained from all participants.
Pathological examination and immunohistochemistry
Pathological examinations were carried out by two pa-
thologists at the Department of Human Pathology of
Juntendo University. To avoid chemotherapy-related ef-
fects, we used biopsy specimens to examine biomarkers
including Ki67. Biopsy specimen fixation was started
within 1 minute after the biopsy, employing 15% buff-
ered formalin, and was continued for 24 hr. Samples
were then processed and embedded in paraffin. Sections
4 μm in thickness were cut and deparaffinised. Antigen
retrieval was accomplished in citrate buffer solution
(pH6.0) at 98°C for 45 minutes following endogenous
peroxidase blocking with 0.3% hydrogen peroxide in
methanol. Samples were incubated in monoclonal anti-
body against Ki67 (MIB-1, Dako, Denmark) (1:400) at
4°C overnight and then developed with 3,3′-diamino-
benzidine. Cells positive for nuclear Ki67 were counted
in at least 500 cancer cells in one hot spot for each of
the biopsy specimens. ER and PR were judged to be
positive when more than 10% of the nuclei of cancer
cells were stained. HER2 was judged to be positive if
more than 10% of tumour cells showed strong staining of
the entire cell membrane, or HER2/neu gene amplification
was confirmed by fluorescence in situ hybridisation.
As indicated above, we excluded such HER2-positive
tumours in this study. Nuclear grade was judged based
on the modified Bloom-Richardson histologic grades
[17]. Chemotherapy effects were determined employing
operative specimens and we defined pCR as invasive nest
disappearance based only on the primary breast tumour,
i.e. without lymph node evaluation.
Statistical analysis
Using JMP® 9 (SAS Institute Inc., Cary, NC, USA), we
applied Fisher’s exact test to examine the independence
of two categorical variables. For comparison of mean
values such as patient age and tumour size, examinations
of unpaired data were carried out with the two-sided
Student’s t-test or Wilcoxon rank sum test, according to
the data distribution. Kaplan-Meier curves were estimated
and the logrank test was applied for comparisons of the
survival distributions of two populations.
The optimal Ki67 cut-off value predicting pCR was de-
termined using Receiver Operating Characteristic (ROC)
curve analysis. The curve was created by plotting the
Figure 1 ROC curve analysis revealed 35% to be the optimal
Ki67 cut-off value for distinguishing between pCR and non-pCR
cases. ROC curve analysis revealed that, in the 10% to 50% Ki67
range, 35% was the optimal cut-off value for distinguishing pCR
from non-pCR cases among our 114 patients. At 35%, the specificity
and sensitivity were 0.79 and 0.73, respectively.
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rate herein) on the y-axis versus the false positive fraction
(=1-specificity) on the x-axis for each Ki67 value tested in
the 10% to 50% range. With this statistical method, the best
possible prediction point is in the upper left corner, with
coordinates of 0 and 1 in the ROC space, and is referred to
as the perfect classification. We determined the optimal
Ki67 value to be that nearest the perfect classification.
Results
Factors influencing chemo-effect
Clinicopathological features of patients and chemo-effects
are presented in Table 1. All biomarkers were determined
using biopsy specimens. The proportions of patients
with each stage of breast cancer were; IIA: 42% (48 cases),
IIB: 45% (51 cases), IIIA: 11% (12 cases) and IIIB: 3%
(3 cases). The pCR rate was 10% (11 cases), which is
approximately half of the average for all subtypes. The
response of PR-negative tumours to NAC was significantly
better than that of PR-positive tumours (p < 0.05). Ki67
was another factor related to the chemo-effect. Tumours
with high Ki67 expression showed better responses to
chemotherapy (p < 0.01) (Table 1 and Additional file 1:
Figure S1), while no direct relationship was seen between
PR status and Ki67 expression (Additional file 2: Figure S2).
Ki67 cut-off value
Next, using ROC curve analysis, we endeavoured to
identify the Ki67 cut-off value which distinguishes pCR
from non-pCR cases (Figure 1). The area under the
curve (AUC), a diagnostic index, was 0.75, indicating
this analysis to have moderate accuracy based on theTable 1 Clinicopathological features of 114 patients and
chemo-effects
pCR non-pCR p value
n 11 103
Mean age (SD) 54.6 (16.4) 50.9 (11.1) n.s.
Mean tumour sizea
(mm) (SD)
35.9 (18.1) 36.0 (15.7) n.s.
Histology
Ductal 11 98 n.s.
Lobular 0 5
High nuclear grade 27% (3/11) 22% (22/99) n.s.
ERb 100% (114/114) 100% (114/114) n.s.
PRb 45% (5/11) 78% (80/103) <0.05
Mean Ki67 (%) (SD)c 43.0 (30.0) 33.6 (18.1) <0.01
ER: estrogen receptor, PR: progesterone receptor, n.s.: not significant.
aclinical size measured by ultrasound before treatments.
brates of positive (more than 10% of the nuclei of cancer cells) cases.
cdot chart shown in Additional file 1: Figure S1.
The NAC response was significantly better in patients with tumours highly
expressing Ki67 (p < 0.01). PR-negative tumours also showed better responses
to chemotherapy (p < 0.05).AUC value being between 0.9 and 0.7 [18]. In the 10%
to 50% range, testing in 5% increments, we identified
the Ki67 value nearest the perfect classification, as this
would be the most effective cut-off Ki67 value for pre-
dicting pCR. The plot with 35% as the Ki67 cut-off
value, (coordinates 0.21 and 0.73) was closest to the
perfect classification. Thus, we concluded 35% to be
optimal Ki67 cut-off value for distinguishing pCR from
non-pCR cases among our 114 patients (Specificity:
0.79, Sensitivity: 0.73). The pCR rates clearly differed
between cases with Ki67 expressions above and below
this cut-off value, at 27% and 4%, respectively.
Patient outcomes
One hundred and ten patients (96%) were given adjuvant
endocrine therapy after surgery. Among these 110, 75
patients had received aromatase inhibitors while the re-
mainder were administered Selective Estrogen Receptor
Modulators. During the median 58-month follow-up
period (9–88 months), 20 patients (18%), none of whom
had shown pCR, developed recurrent disease. Thirteen
of these patients died of their breast cancer. When the
outcomes were analysed according to chemo-effect,
Kaplan-Meier curves showed that the pCR group had
higher rates of disease-free survival (DFS) and overall
survival (OS) than the non-pCR group (100% vs 78.1%,
100% vs 87.7%, respectively at 60 months), although
statistical significance could not been determined because
there were no events in the pCR group (Figure 2). Next,
Figure 2 Kaplan-Meier curves of 114 patient outcomes according to chemotherapy effect. Twenty patients, none of whom had shown
pCR, developed recurrent disease during the median 58-month follow-up period. Thirteen of these patients died due to breast cancer. The pCR
group had higher rates of DFS and OS than the non-pCR group (100% vs 78.1%, 100% vs 87.7%, respectively at 60 months), although statistical
significance could not be determined due to the lack of events in the pCR group.
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patient outcomes. Kaplan-Meier curves with a 35% cut-off
point for Ki67 are shown in Figure 3. Neither 35% nor any
of the other Ki67 cut-off values (10-50%) showed a clinic-
ally meaningful relationship between Ki67 expression and
either DFS or OS.
Validation of the Ki67 cut-off value
Our results clearly showed a 35% cut-off value for Ki67
to distinguish pCR from non-pCR luminal breast cancer
cases. To validate this cut-off value, we investigated patients
with HER2-negative luminal tumours who underwent sur-
gery at our institution during the 18-month period starting
in April 2010, regardless of whether or not they receivedFigure 3 Kaplan-Meier curves of 114 patient outcomes according to K
10 to 50%, there was no relationship between Ki67 expression and patientNAC. There were 196 patients and their clinicopathological
features are shown in the Table 2. Compared to the 114 de-
scribed above, this population includes relatively low-risk
cases, i.e. 45% of these 196 patients had Stage I while the
114 all had stage II or III disease. Only 31% of this popula-
tion (61 of 196) received (neo-) adjuvant chemotherapy
plus endocrine therapy while 65% were given only endo-
crine therapy. Nine patients (5%) developed recurrent dis-
ease and two of them died during the median 29-month
follow-up period (5–40 months). The observation period
was, unfortunately, relatively short because only data from
the time period when Ki67 examinations started to be
routinely performed for all surgical cases in our hospital
were available. Nonetheless, DFS differed significantlyi67 expression (cut-off: 35%). With Ki67 cut-off values ranging from
outcomes.
Table 2 Clinicopathological features and outcomes of 196 HER2-negative luminal breast cancer patients
Recurrence No recurrence p value
n 9 187
Mean age (SD) 55.3 (13.9) 55.9 (12.1) n.s.
Stagea
I 2 87
IIA or B 4 96 <0.01
IIIA or B 3 4
Histology
Ductal 7 161
Lobular 2 11 n.s.
Others 0 15
High nuclear grade 11% (1/9) 4% (7/181) n.s.
High histological grade 22% (2/9) 4% (6/141) n.s.
ERb 100% (9/9) 100% (187/187) n.s.
PRb 67% (6/9) 78% (145/187) n.s.
Mean Ki67 (%) (SD) 37.9 (21.7) 24.1 (18.5) <0.05
(Neo-) adjuvant therapy
Endocrine + chemotherapy 9 52
Endocrine therapy only 0 127
Chemotherapy only 0 1
None 0 7
n.s.: not significant.
adetermined according to pathological findings.
bpercentage of positive (more than 10% of the nuclei of cancer cells) cases.
There were 196 patients with HER2-negative luminal tumours who underwent surgery during the 18-month period starting in April 2010. Compared to the
114 described above, this population includes relatively low-risk patients, i.e. 45% of the 196 patients had Stage I while all of the 114 had stage II or III disease.
(Only 31% of this population received NAC plus endocrine therapy).
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than 35% versus lower than 35% (p < 0.01) (Figure 4),
while a similar but smaller difference was observed with
a Ki67 cut-off value of 25% (p < 0.05) in those with values
ranging from 10 to 50%.
Discussion
In this study, the pCR rate was 10%, which is within the
range established by previous studies (6-11%) focusing on
HER2-negative and hormone receptor-positive patients
[4,19,20]. Tumours with high Ki67 expression and/or
PR-negativity showed a good response to chemotherapy.
As illustrated in Additional file 2: Figure S2, there was
no clear correlation between PR status and Ki67 expres-
sion. While PR-negative tumours might now have to be
regarded as luminal B-like [21,22], we did not differentiate
these from PR-positive cases in the current study since
this is a topic awaiting further careful consideration. There
was no meaningful relationship between Ki67 expression
and either DFS or OS. This is possibly because all patients
enrolled in the present study received NAC, meaning
that only relatively high-risk tumours were selected
and also that some patients with tumours showing highKi67 expression may have benefitted from salvage ther-
apy with NAC and thus remained recurrence-free.
Our results support those of Fasching et al., who per-
formed an elegant analysis of data from a large group of
patients [20]. Employing two statistical models, they
investigated the predictive and prognostic values of Ki67
in all subtype groups. Ki67 cut-off values between 36%
and 40% were found to predict pCR to NAC for the
hormone receptor-positive and HER2-negative breast
cancer cases. The pCR group had more favourable out-
comes, despite this population having a higher Ki67
proliferation rate. Another study from the GeparTrio
trial similarly showed that tumours with Ki67 higher
than 35%, as a group, had the best chemo-effect [23].
Our results are consistent with theirs, though we analysed
Ki67 employing a different approach. In the current study,
pCR was frequent in patients whose tumours showed
Ki67 expression higher than 35% and all patients who
obtained pCR remained recurrence-free. On the con-
trary, in the 196 patients recruited for validation, DFS
was significantly lower for tumours with Ki67 higher
than 35%. These results suggest that the population with
Ki67 higher than 35% might benefit from chemotherapy,
Figure 4 Kaplan-Meier curves of DFS according to Ki67 (cut-off: 35%) in 196 HER2-negative luminal breast cancer patients. Of these 196
patients, nine developed recurrent disease during the median 29-month follow-up period. Despite the short observation period, DFS differed
significantly between patients whose tumours had Ki67 expression higher than 35% versus lower than 35% (p < 0.01).
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we explored in the present study.
Obtaining pCR in luminal cases is sometimes ques-
tioned as von Minckwitz et al. indicated that pCR might
be less significant than previously thought in luminal
A-like and luminal B/HER2-positive-like cases [4].
However, our results do not necessarily conflict with
the arguments of von Minckwitz and colleagues as our
patient population included considerable numbers of
luminal B-like cases, in which clinical benefit was
clearly obtained in their study. The same logic can be
applied to other reports showing the advantages of
obtaining pCR in the luminal breast cancer population
[16,20]. We speculate that further clinically significant
observations might be made in identifying a subpopu-
lation among those with luminal HER2-negative tu-
mours who could be salvaged by chemotherapy, rather
than concentrating solely on distinguishing between
luminal A-like and B-like tumours with Ki67 cut-off
values such as 14%.
While our study has the limitations of being retrospective
and having a relatively small number of subjects, it has the
major advantage of consistency in immunostaining results.
Using only biopsy specimens, that had been immediately
fixed after sample collection, all processing steps and
evaluations were performed in a single institution, an
important feature of our study given that inconsisten-
cies in the assessment of Ki67 among institutions have
yet to be resolved [21,24-26]. Evaluation employing
biopsy specimens might be affected to some degree by
heterogeneity within a single tumour, as compared toexaminations based on whole operative specimens. How-
ever, given the goal of this study, we believe that avoiding
the possible effects of NAC outweighs any possible disad-
vantages associated with tumour heterogeneity.
Conclusion
Though it is necessary to examine long-term patient
outcomes to obtain evidence supporting our results, we
identified a Ki67 cut-off value, 35%, for selecting patients
who would benefit from chemotherapy.
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